Name

Hyeon Seok EOM, M.D., Ph.D.(adjunct professor)

Faculty Appointment
(title, department)

Professor, Department of Cancer Biomedical Science, NCC-GCSP
Head, Center for Clinical Trials
Chief,Hematopoietic Stem Cell Transplantation Center
Head, Internal Medicine department, National Cancer Center, Korea

Area of Expertise

Hematologic malignancies/Transplantation immunobiology

E-mail

hseom@ncc.re.kr

Highest Academic Qualification

Chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Korea
Senior Scientist, Hematologic Malignancy Branch, Research Institute, Division of Translational & Clinical Research II, National Cancer Center, Korea
Head, Internal Medicine department, National Cancer Center, Korea

Work Experience

Head, Internal Medicine department, National Cancer Center (2011-present)
Senior Scientist, Hematologic Malignancy Branch, Research Institute, Division of Translational & Clinical Research II, National Cancer Center, Korea (2007-2013)
Chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Korea (2005-present)
Research Fellow, BMT section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA (2002-2004)
Assistant Professor, Department of Internal Medicine and Hemato-Oncology College of Medicine, The Catholic University of Korea (2001-2004)

Educational Background

Ph.D. The Catholic University Postgraduate School, Seoul, Korea (1997- 2001)
M.D. The Catholic University College of Medicine, Seoul, Korea (1983-1989)
M.M.S.The Catholic University Graduate School, Seoul, Korea (1991-1993)

Research Interests

Dr. Eom is a chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic. His research interests are focused on hematologic malignancies, especially lymphoma and multiple myeloma, and transplantation immunobiology. He was a senior scientist in Hematologic Malignancy Branch, Research Institute. He is interested in genetically modified donor lymphocyte infusion to the recipients who are in mixed chimera so that this DLI produce graft-vs.-lymphoma/myeloma effects without GVHD.

International Collaboration

Member, SWOG (2012–present)